Introduction {#sec1}
============

Being the third most common genitourinary malignancy, renal cell carcinoma (RCC) represents about 3% of all cancers in adults \[[@cit0001]\]. The RCC is the seventh most frequent cancer in men and the ninth in women worldwide \[[@cit0002]\]. Due to a significant improvement in diagnostic radiology, more incidental RCC are observed. However, 25% of patients with RCC still present metastases at first diagnosis \[[@cit0003]\]. Numerous risk factors for RCC have been indicated, including cigarette smoking, obesity, cadmium and asbestos intoxication, diabetes mellitus, hypertension and chronic dialysis \[[@cit0004]\]. Regarding the histological aspect of kidney cancer, it is mostly composed of clear cell RCC (ccRCC), which accounts for over 70% of RCC cases \[[@cit0005]\].

In localized RCC, the only high-quality evidenced treatment is surgical resection \[[@cit0004]\]. Relevant advances in surgical treatment, immunotherapy and targeted therapy in RCC were observed. Nevertheless, long-term outcomes are still not satisfactory, particularly due to common local recurrences, distal metastases and limited drug response \[[@cit0006]\]. Under those circumstances, an improvement in RCC patients' management could be obtained by developing novel, easily obtainable and cheap prognostic markers which might help select patients who would benefit most from additional postoperative care \[[@cit0007], [@cit0008]\]. It is commonly known that blood is full of tumor-associated biomarkers, such as pro-inflammatory cells, including neutrophils and platelets. As evidenced by a multitude of research, the systemic inflammatory reaction plays a crucial role in tumorigenesis \[[@cit0009]\].

Numerous studies have linked neutrophilia with poor prognosis, e.g. in cervical or prostate cancer patients \[[@cit0010], [@cit0011]\]. Elevated neutrophil count in peripheral blood has been identified as a predictor of shorter overall survival (OS) in metastatic RCC patients \[[@cit0012]\].

Increased platelet count was associated with poor prognosis in pancreatic, gastric, colorectal, endometrial and ovarian cancers \[[@cit0013]--[@cit0017]\]. Mean platelet volume (MPV) is a widely used index of platelet activation that has been linked with various inflammatory states \[[@cit0018]\]. Decreased MPV was associated with decreased survival in non-small cell lung cancer and esophageal cancer patients \[[@cit0019], [@cit0020]\]. In RCC patients, two studies confirmed MPV as an independent prognostic factor for cancer-specific survival (CSS) \[[@cit0021], [@cit0022]\] and one study proved it to be an independent prognostic factor of OS \[[@cit0023]\].

Up to now, there are no studies that have used both blood cell parameters as predictive factors in RCC, or in any other cancer. That is the reason why we attempted to evaluate the influence of neutrophil-to-mean platelet volume ratio (NMPVR) on OS and CSS in patients treated with radical or partial nephrectomy for localized (M0) ccRCC.

Material and methods {#sec2}
====================

In this retrospective study, we analyzed 344 who underwent partial or radical nephrectomy for M0 ccRCC at our institution between January 2003 and December 2012. The NMPVR was calculated as neutrophil count divided by mean platelet volume. Information on survival was obtained from the Polish Ministry of Interior and Administration, which stores, among other data, the exact date of death of every Polish citizen since the mid-1980s. Cause of death was accessed from the Polish National Cancer Registry and the National Health Fund. Complete follow-up data were available for all analyzed patients.

Statistical analysis {#sec2.1}
--------------------

Quantitative data are presented as medians and interquartile ranges. Qualitative data are presented as frequencies. Comparisons of baseline characteristics and laboratory and pathological findings were performed using the Mann-Whitney *U* test and the χ^2^ test, where appropriate. Based on the median NMPVR, the study population was divided into two groups: the high NMPVR group with NMPVR higher than or equal to the median, and the low NMPVR group with NMPVR lower than median. Differences in overall and cancer-specific survival between groups were compared using the Kaplan-Meier method and log-rank test. The Cox proportional hazards regression model was applied to perform univariate and multivariate analyses. Variables with a *p*-value lower than 0.05 in univariate analysis were subjected to multivariable analysis. Statistical analyses were performed using the Statistica 13.1 software with the Medical Bundle (StatSoft Inc., Tulsa, Oklahoma, USA).

Results {#sec3}
=======

The median follow-up was 2184 (interquartile range: 1553--3243) days. During the observation period both overall and cancer-specific survival rates were higher in patients with low NMPVR than in patients with high NMPVR ([Table I](#t0001){ref-type="table"}, [Figures 1](#f0001){ref-type="fig"}, [2](#f0002){ref-type="fig"}). Comparison of baseline characteristics and laboratory and pathological findings across groups of patients with low and high NMPVR who underwent nephrectomy due to localized ccRCC is presented in [Table I.](#t0001){ref-type="table"} Briefly, there were no significant differences between patients with high and low NMPVR in terms of sex, age, lymph node involvement and sarcomatoid feature presence. Patients with higher NMPVR values were more often diagnosed with advanced disease, tumor necrosis and higher tumor grade. This group also underwent radical nephrectomy more frequently. The NMPVR was significantly associated with overall survival and cancer-specific survival, both in univariate and in multivariate analysis, after adjustment for clinicopathological covariates ([Table II](#t0002){ref-type="table"}).

###### 

Comparison of baseline characteristics, laboratory and pathological findings across groups of patients with low and high NMPVR values

  Parameter                                  NMPVR                                         
  ------------------------------------------ ---------------------- ---------------------- ----------------------------------------
  Sex:                                       0.08                                          
   Male                                      46%                    55%                    
   Female                                    54%                    45%                    
  Age \[years\]                              64.0 (55.0--71.0)      62.0 (54.0--69.0)      0.2
  BMI \[kg/m^2^\]                            27.2 (24.5--30.7)      27.1 (24.6--30.2)      0.82
  Hemoglobin \[g/dl\]                        13.7 (12.8--14.7)      13.9 (12.4--15.1)      0.71
  Red blood cell count \[× 10^6^/mm^3^\]     4.47 (4.25--4.77)      4.61 (4.29--4.9)       0.11
  White blood cell count \[× 10^6^/mm^3^\]   5.6 (5.0--6.4)         8.0 (6.8--9.1)         \< 0.0001
  Lymphocytes \[× 10^3^/mm^3^\]              1.9 (1.5--2.4)         1.9 (1.6--2.5)         0.26
  Neutrophils \[× 10^3^/mm^3^\]              3.1 (2.5--3.6)         5.0 (4.1--5.9)         \< 0.0001
  Monocytes \[× 10^3^/mm^3^\]                0.4 (0.3--0.5)         0.5 (0.4--0.6)         \< 0.0001
  Platelets \[× 10^3^/mm^3^\]                219.0 (175.0--260.0)   267.0 (220.0--330.0)   \< 0.0001
  MPV \[fl\]                                 10.4 (9.0--11.8)       8.5 (7.7--9.8)         \< 0.0001
  Sarcomatoid feature:                       0.39                                          
   Present                                   1%                     2%                     
   Absent                                    99%                    98%                    
  pT stage:                                  0.009                                         
   pT1/pT2                                   84%                    72%                    
   pT3/pT4                                   16%                    28%                    
  Lymph node involvement:                    0.54                                          
   pN0                                       97%                    96%                    
   pN1                                       3%                     4%                     
  TNM stage:                                 0.003                                         
   I                                         73%                    55%                    
   II                                        10%                    15%                    
   III                                       17%                    29%                    
   IV                                        0%                     1%                     
  Tumor grade:                               0.005                                         
   G1/G2                                     77%                    63%                    
   G3/G4                                     23%                    37%                    
  Tumor size \[mm\]                          45.0 (35.0--60.0)      60.0 (40.0--75.0)      0.001
  Nephrectomy:                               0.04                                          
   Partial                                   39%                    28%                    
   Radical                                   61%                    72%                    
  Tumor necrosis:                            0.04                                          
   Present                                   11%                    19%                    
   Absent                                    89%                    81%                    
  Overall survival                           68%                    58%                    0.002[\*](#tf1-1){ref-type="table-fn"}
  Cancer-specific survival                   86%                    77%                    0.006[\*](#tf1-1){ref-type="table-fn"}

log-rank. Continuous variables are presented as median (interquartile range). Dichotomous variables are presented as percentages. BMI -- body mass index, MPV -- mean platelet volume, NMPVR -- neutrophil-to-mean platelet volume ratio.

###### 

Prognostic value of NMPVR in patients with localized ccRCC who underwent nephrectomy -- univariate and multivariate analyses

  Parameter                                                   HR     95% CI       *P*-value
  ----------------------------------------------------------- ------ ------------ -----------
  Overall mortality:                                                              
   Univariate analysis                                        3.4    2.16--5.47   \< 0.0001
   Multivariate analysis[\*](#tf2-1){ref-type="table-fn"}     2.24   1.4--3.59    0.0008
  Cancer-specific mortality:                                                      
   Univariate analysis                                        3.74   2.18--6.61   \< 0.0001
   Multivariate analysis[\*\*](#tf2-2){ref-type="table-fn"}   2.02   1.08--3.77   0.03

Adjusted for age (≥ 65/\< 65), pT stage, nephrectomy (partial/radical), sarcomatoid feature, presence of tumor necrosis, tumor grade, lymph node involvement.

Adjusted for age (≥ 65/\< 65), pT stage, nephrectomy (partial/radical), presence of tumor necrosis, tumor grade, lymph node involvement. ccRCC -- clear cell renal cell carcinoma, HR -- hazard ratio, CI -- confidence interval, NMPVR -- neutrophil-to-mean platelet volume ratio.

![Kaplan-Meier curves for overall survival of ccRCC patients with high and low NMPVR\
NMPVR -- neutrophil-to-mean platelet volume ratio, ccRCC -- clear cell renal cell carcinoma.](AMS-16-5-36137-g001){#f0001}

![Kaplan-Meier curves for cancer-specific survival of ccRCC patients with high and low NMPVR\
NMPVR -- neutrophil-to-mean platelet volume ratio, ccRCC -- clear cell renal cell carcinoma.](AMS-16-5-36137-g002){#f0002}

Discussion {#sec4}
==========

Until now, there have been no studies recognizing the new blood-based biomarker NMPVR as a prognostic factor either in RCC or in any other neoplasm. Our study is the first one to determine the prognostic value of NMPVR in patients suffering from cancer. We demonstrated that neutrophil-to-mean platelet volume ratio was an independent prognostic factor for both cancer-specific and overall survival of RCC patients undergoing radical or partial nephrectomy. In addition, the group with baseline NMPVR ≥ 0.41 was more likely to be treated with radical nephrectomy and has more advanced disease, with higher prevalence of tumor necrosis and a higher Fuhrman grade.

Many papers have raised the topic of neutrophilia as a prognostic marker in several cancers, including RCC \[[@cit0010]--[@cit0012]\]. Donskov *et al.* identified increased neutrophil count of over 6 × 10^9^/l in peripheral blood as an independent predictor for shorter OS in RCC patients. However, contrary to our study, their study group was treated with IL-2 based immunotherapy and patients presented metastases \[[@cit0012]\].

Three studies recognized MPV as a possible predictor of survival in RCC patients treated solely surgically. Seles *et al.* defined MPV lower than 9.5 fl as a negative prognostic factor for CSS \[[@cit0022]\]. Prokopowicz *et al.* proposed the MPV cut-off value as 10.1 fl, given that patients with lower values suffered from significantly higher cancer-specific mortality \[[@cit0021]\]. Yun *et al.* discovered that patients with MPV lower than 7.5 fl had shorter OS \[[@cit0023]\].

Even though it has not been examined before, we hypothesize that NMPVR might be utilized in oncology, as it simultaneously evaluates two independent cellular lines involved in inflammatory processes, namely neutrophils and platelets. It has been proven that not only the tumor's oncological characteristics have an impact on the outcome, but also the host's inflammatory response to a progressing malignancy \[[@cit0024]\]. Mechanisms involved in the interactions between cancer and inflammation are complicated -- inflammation impacts every single step of tumorigenesis, from tumor initiation to promotion and metastasis formation \[[@cit0009]\].

It has been demonstrated that neutrophil count increases in relation to the systemic inflammatory response against the tumor \[[@cit0025]\]. Expression of NF-κB, STAT3 and KIF1α transcription factors in tumor cells contributes to an increase in concentration of several cytokines (IL-1, IL-6, IL-8 and IFN-γ), leading to neutrophil recruitment and their upsurge in peripheral blood. Neutrophils release reactive oxygen species which damage DNA and may lead to promotion of tumor development \[[@cit0026]--[@cit0028]\]. Additionally, neutrophils produce inflammatory (e.g. IL-1, IL-6, IL-8) and proangiogenic cytokines (e.g. epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF)), facilitating malignant disease development and metastases \[[@cit0029], [@cit0030]\].

Platelets play a crucial role in tumor progression, angiogenesis and metastasis by directly interacting with tumor cells, promoting their proliferation as well as the secretion of angiogenic and mitogenic proteins, including VEGF, PDGF, thrombospondins, endostatins and hepatocyte growth factors \[[@cit0031]--[@cit0033]\]. Circulating tumor cells (CTCs) lead to activation and aggregation of platelets, which correlate with their metastatic potential. Platelets shield CTCs from immune cells and cytotoxicity mediated by TNF-α. Consequently, there exists specific reciprocal feedback between platelets and tumor cells' activity \[[@cit0034]\]. The MPV was recognized as one of the first markers of platelet activation. Furthermore, decreased MPV is linked with excessive degradation of large platelets in severe inflammatory diseases, which could be reversed in the course of anti-inflammatory therapy \[[@cit0018]\].

We are aware that the present paper is not without limitations. Firstly, our study was single-centered and retrospective in nature. Secondly, we were not able to obtain postoperative therapy data. Thirdly, our study population consisted of Polish citizens only. The application to other ethnic groups still needs further investigation. Larger prospective randomized studies are needed to validate and extend our findings.

In conclusion, our study has revealed that NMPVR may be used in everyday urological practice as a cheap and easily obtainable prognostic marker for OS and CSS in patients with localized ccRCC. It might be used to identify patients who would benefit most from additional, more intense postoperative care.
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